Jedd D Wolchok

List of Publications by Year
in descending order

236	113,116	905 116	1385 222
papers	citations	h-index	g-index

251	251	251	75553
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. New England Journal of Medicine, 2010, 363, 711-723.	13.9	13,065
2	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. New England Journal of Medicine, 2015, 373, 23-34.	13.9	6,773
3	Mutational landscape determines sensitivity to PD-1 blockade in nonâ€“small cell lung cancer. Science, 2015, 348, 124-128.	6.0	6,756
4	Cancer immunotherapy using checkpoint blockade. Science, 2018, 359, 1350-1355.	6.0	4,274
5	Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. New England Journal of Medicine, 2011, 364, 2517-2526.	13.9	4,074
6	Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. New England Journal of Medicine, 2014, 371, 2189-2199.	13.9	3,753
7	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 2017, 377, 1345-1356.	13.9	3,589
8	Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria. Clinical Cancer Research, 2009, 15, 7412-7420.	3.2	2,857
9	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics, 2019, 51, 202-206.	9.4	2,702
10	Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma. New England Journal of Medicine, 2015, 372, 2006-2017.	13.9	2,489
11	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 2019, 381, 1535-1546.	13.9	2,484
12	Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science, 2016, 351, 1463-1469.	6.0	2,445
13	Immune Checkpoint Blockade in Cancer Therapy. Journal of Clinical Oncology, 2015, 33, 1974-1982.	0.8	2,220
14	PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Science Translational Medicine, 2016, 8, 328rv4.	5.8	1,844
15	Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma. New England Journal of Medicine, 2012, 366, 925-931.	13.9	1,836
16	Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. Journal of Clinical Oncology, 2015, 33, 1889-1894.	0.8	1,809
17	iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncology, The, 2017, 18, e143-e152.	5.1	1,612
18	Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. New England Journal of Medicine, 2018, 378, 1976-1986.	13.9	1,495

#	Article	IF	Citations
19	Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell, 2015, 162, 974-986.	13.5	1,408
20	T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature, 2017, 545, 60-65.	13.7	1,280
21	Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of antiâ€“CTLA-4 therapy against melanoma. Journal of Experimental Medicine, 2013, 210, 1695-1710.	4.2	1,203
22	RECIST 1.1â€”Update and clarification: From the RECIST committee. European Journal of Cancer, 2016, 62, 132-137.	1.3	1,143
23	STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discovery, 2018, 8, 822-835.	7.7	1,108
24	Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncology, The, 2018, 19, 1480-1492.	5.1	1,089
25	Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncology, The, 2010, 11, 155-164.	5.1	1,075
26	Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. Journal of Clinical Oncology, 2017, 35, 785-792.	0.8	930
27	The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nature Reviews Clinical Oncology, 2016, 13, 273-290.	12.5	909
28	Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. Journal of Clinical Oncology, 2015, 33, 3193-3198.	0.8	892
29	Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA - Journal of the American Medical Association, 2016, 315, 1600.	3.8	857
30	Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature, 2017, 551, 512-516.	13.7	854
31	Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncology, The, 2016, 17, 1558-1568.	5.1	827
32	Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell, 2018, 33, 843-852.e4.	7.7	827
33	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. New England Journal of Medicine, 2015, 373, 1270-1271.	13.9	785
34	Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nature Communications, 2016, 7, 10391.	5.8	784
35	KIT as a Therapeutic Target in Metastatic Melanoma. JAMA - Journal of the American Medical Association, 2011, 305, 2327.	3.8	755
36	Overcoming resistance to checkpoint blockade therapy by targeting PI3KÎ³ in myeloid cells. Nature, 2016, 539, 443-447.	13.7	661

#	Article	IF	Citations
37	Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature, 2017, 545, 452-456.	13.7	643
38	Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. Journal of Clinical Oncology, 2016, 34, 1510-1517.	0.8	627
39	Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy. Science Translational Medicine, 2014, 6, 226ra32.	5.8	590
40	Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. Journal of Experimental Medicine, 2013, 210, 1389-1402.	4.2	562
41	A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. Nature, 2017, 551, 517-520.	13.7	532
42	Programmed Death-Ligand 1 Expression and Response to the Antiâ€“Programmed Death 1 Antibody Pembrolizumab in Melanoma. Journal of Clinical Oncology, 2016, 34, 4102-4109.	0.8	528
43	Determinants of COVID-19 disease severity in patients with cancer. Nature Medicine, 2020, 26, 1218-1223.	15.2	501
44	Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. Clinical Cancer Research, 2016, 22, 5487-5496.	3.2	480
45	The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Research, 2020, 30, 507-519.	5.7	480
46	Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas. Cancer Cell, 2012, 22, 668-682.	7.7	469
47	Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. Clinical Cancer Research, 2016, 22, 2908-2918.	3.2	459
48	Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. Journal of Clinical Oncology, 2017, 35, 226-235.	0.8	458
49	Immune Modulation in Cancer with Antibodies. Annual Review of Medicine, 2014, 65, 185-202.	5.0	455
50	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. Journal of Clinical Oncology, 2022, 40, 127-137.	0.8	446
51	Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial. Journal of Clinical Oncology, 2015, 33, 1191-1196.	0.8	445
52	The many faces of the anti-COVID immune response. Journal of Experimental Medicine, 2020, 217, .	4.2	437
53	Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. JAMA Oncology, 2019, 5, 471.	3.4	426
54	MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Science Translational Medicine, 2018, 10, .	5.8	425

#	Article	IF	Citations
55	The hallmarks of successful anticancer immunotherapy. Science Translational Medicine, 2018, 10, .	5.8	419
56	Targeting T Cell Co-receptors for Cancer Therapy. Immunity, 2016, 44, 1069-1078.	6.6	418
57	Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial. Clinical Cancer Research, 2010, 16, 2861-2871.	3.2	404
58	Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers. Journal of Clinical Oncology, 2018, 36, 1685-1694.	0.8	399
59	Classification of current anticancer immunotherapies. Oncotarget, 2014, 5, 12472-12508.	0.8	395
60	Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. Cancer Cell, 2018, 33, 581-598.	7.7	393
61	Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Nonâ€“Small Cell Lung Cancer Treated With Nivolumab. JAMA Oncology, 2019, 5, 1411.	3.4	388
62	Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. Cell Reports, 2015, 13, 412-424.	2.9	387
63	Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient. Cell, 2017, 170, 927-938.e20.	13.5	368
64	CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nature Medicine, 2021, 27, 1280-1289.	15.2	365
65	Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. Journal of Clinical Oncology, 2017, 35, 3807-3814.	0.8	364
66	The Abscopal Effect Associated With a Systemic Anti-melanoma Immune Response. International Journal of Radiation Oncology Biology Physics, 2013, 85, 293-295.	0.4	360
67	Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma. JAMA - Journal of the American Medical Association, 2014, 311, 2397.	3.8	359
68	Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nature Reviews Clinical Oncology, 2022, 19, 37-50.	12.5	350
69	Stereotactic Radiosurgery for Melanoma BrainÂMetastases in Patients Receiving Ipilimumab: Safety Profile and Efficacy of Combined Treatment. International Journal of Radiation Oncology Biology Physics, 2015, 92, 368-375.	0.4	334
70	CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors. Nature Immunology, 2020, 21, 298-308.	7.0	326
71	Monocytic CCR2+ Myeloid-Derived Suppressor Cells Promote Immune Escape by Limiting Activated CD8 T-cell Infiltration into the Tumor Microenvironment. Cancer Research, 2012, 72, 876-886.	0.4	313
72	Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade. Cell, 2019, 178, 933-948.e14.	13.5	301

#	Article	IF	Citations
73	Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. Journal of Clinical Oncology, 2018, 36, 850-858.	0.8	288
74	Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ TÂcells in tumors. Immunity, 2021, 54, 1561-1577.e7.	6.6	260
75	Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors. Clinical Cancer Research, 2016, 22, 1364-1370.	3.2	251
76	Adipocyte-Derived Lipids Mediate Melanoma Progression via FATP Proteins. Cancer Discovery, 2018, 8, 1006-1025.	7.7	248
77	Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. Cancer Immunology Research, 2016, 4, 383-389.	1.6	247
78	Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. Journal of Clinical Oncology, 2017, 35, 3815-3822.	0.8	244
79	The efficacy of antiâ€PDâ€1 agents in acral and mucosal melanoma. Cancer, 2016, 122, 3354-3362.	2.0	236
80	Coupling and Uncoupling of Tumor Immunity and Autoimmunity. Journal of Experimental Medicine, 1999, 190, 1717-1722.	4.2	232
81	The Mechanism of Anti-CTLA-4 Activity and the Negative Regulation of T-Cell Activation. Oncologist, 2008, 13, 2-9.	1.9	222
82	Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation. PLoS ONE, 2010, 5, e10436.	1.1	222
83	Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. Clinical Cancer Research, 2018, 24, 4960-4967.	3.2	222
84	PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance. Nature Immunology, 2019, 20, 1231-1243.	7.0	217
85	Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. Nature Medicine, 2020, 26, 1114-1124.	15.2	216
86	RECIST 1.1 â€“ Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. European Journal of Cancer, 2016, 62, 138-145.	1.3	211
87	Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers. Cancer Discovery, 2020, 10, 1121-1128.	7.7	206
88	Conserved Interferon-Î³ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. Cancer Cell, 2020, 38, 500-515.e3.	7.7	203
89	Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma. JAMA Oncology, 2015, 1, 433.	3.4	201
90	Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine. Nature Communications, 2020, 11, 4011.	5.8	198

#	Article	IF	Citations
91	Agonist Anti-GITR Antibody Enhances Vaccine-Induced CD8+ T-Cell Responses and Tumor Immunity. Cancer Research, 2006, 66, 4904-4912.	0.4	195
92	OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. Journal of Experimental Medicine, 2009, 206, 1103-1116.	4.2	195
93	Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma. , 2015, 3, 23.		190
94	CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours. Nature, 2021, 591, 652-658.	13.7	187
95	Immunotherapy of Melanoma: Facts and Hopes. Clinical Cancer Research, 2019, 25, 5191-5201.	3.2	181
96	Rational design of anti-GITR-based combination immunotherapy. Nature Medicine, 2019, 25, 759-766.	15.2	180
97	Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treatment Reviews, 2014, 40, 1056-1064.	3.4	178
98	CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic. Frontiers in Oncology, 2014, 4, 385.	1.3	175
99	Ipilimumab in patients with cancer and the management of dermatologic adverse events. Journal of the American Academy of Dermatology, 2014, 71, 161-169.	0.6	170
100	First-in-Humans Imaging with ⁸⁹Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting. Journal of Nuclear Medicine, 2020, 61, 512-519.	2.8	170
101	The PTEN pathway in T _{regs} is a critical driver of the suppressive tumor microenvironment. Science Advances, 2015, 1, e1500845.	4.7	167
102	Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study. Journal of Clinical Oncology, 2018, 36, 391-398.	0.8	156
103	Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis. Oncologist, 2016, 21, 848-854.	1.9	154
104	Future cancer research priorities in the USA: a Lancet Oncology Commission. Lancet Oncology, The, 2017, 18, e653-e706.	5.1	153
105	Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab. Clinical Cancer Research, 2016, 22, 4848-4858.	3.2	146
106	Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Research, 2015, 25, 208-224.	5.7	143
107	Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis. Cancer Discovery, 2021, 11, 1212-1227.	7.7	139
108	Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy. Cancer Immunology Research, 2016, 4, 835-844.	1.6	138

#	Article	IF	Citations
109	GITR Pathway Activation Abrogates Tumor Immune Suppression through Loss of Regulatory T-cell Lineage Stability. Cancer Immunology Research, 2013, 1, 320-331.	1.6	135
110	On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Science Translational Medicine, 2015, 7, 280sr1.	5.8	134
111	Modulation of GITR for cancer immunotherapy. Current Opinion in Immunology, 2012, 24, 217-224.	2.4	132
112	Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells. Cancer Immunology Research, 2016, 4, 936-947.	1.6	132
113	Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. Cell, 2021, 184, 4032-4047.e31.	13.5	131
114	Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype. Journal of Experimental Medicine, 2012, 209, 2113-2126.	4.2	130
115	Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. Clinical Cancer Research, 2015, 21, 2289-2296.	3.2	128
116	PD-1 Blockers. Cell, 2015, 162, 937.	13.5	126
117	Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade. Cancer Immunology Research, 2017, 5, 84-91.	1.6	126
118	Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma. JAMA Oncology, 2018, 4, 98.	3.4	125
119	Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. Investigational New Drugs, 2013, 31, 425-434.	1.2	123
120	¹⁸F-FDG PET/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma. Journal of Nuclear Medicine, 2019, 60, 335-341.	2.8	123
121	Computational Algorithm-Driven Evaluation of Monocytic Myeloid-Derived Suppressor Cell Frequency for Prediction of Clinical Outcomes. Cancer Immunology Research, 2014, 2, 812-821.	1.6	122
122	Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors. EBioMedicine, 2016, 6, 50-58.	2.7	113
123	Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. Cell, 2018, 173, 624-633.e8.	13.5	113
124	Non-conventional Inhibitory CD4+Foxp3â^'PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity. Cancer Cell, 2018, 33, 1017-1032.e7.	7.7	112
125	PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. Journal of Clinical Investigation, 2018, 128, 1413-1428.	3.9	111
126	Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. Nature Communications, 2017, 8, 14340.	5.8	110

#	Article	IF	Citations
127	Enhancement of Tumor-Reactive Cytotoxic CD4+ T-cell Responses after Ipilimumab Treatment in Four Advanced Melanoma Patients. Cancer Immunology Research, 2013, 1, 235-244.	1.6	109
128	Combinatorial Cancer Immunotherapies. Advances in Immunology, 2016, 130, 251-277.	1.1	107
129	Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy. , 2014, 2, 7.		105
130	Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy. Molecular Therapy, 2018, 26, 1008-1019.	3.7	103
131	Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade. Cancer Immunology Research, 2018, 6, 189-200.	1.6	102
132	Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells. Science Immunology, 2017, 2, .	5.6	101
133	CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma.. Journal of Clinical Oncology, 2021, 39, 9506-9506.	0.8	101
134	Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor. Cancer Immunology Research, 2014, 2, 70-79.	1.6	100
135	Blockade of surface-bound TGF-Î² on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment. Science Signaling, 2017, 10, .	1.6	100
136	Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment. , 2017, 5, 76.		96
137	Activation of p53 in Immature Myeloid Precursor Cells Controls Differentiation into Ly6c+CD103+ Monocytic Antigen-Presenting Cells in Tumors. Immunity, 2018, 48, 91-106.e6.	6.6	95
138	Safety and Immunogenicity of Tyrosinase DNA Vaccines in Patients with Melanoma. Molecular Therapy, 2007, 15, 2044-2050.	3.7	94
139	Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ TÂcell immunity. Cancer Cell, 2021, 39, 973-988.e9.	7.7	93
140	Self-antigenâ€“specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response. Journal of Experimental Medicine, 2009, 206, 849-866.	4.2	92
141	Antitumour immunity gets a boost. Nature, 2014, 515, 496-498.	13.7	90
142	Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. European Journal of Cancer, 2017, 73, 61-70.	1.3	88
143	Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation. Nature Communications, 2015, 6, 6840.	5.8	87
144	Safety of Inactivated Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitors. Clinical Infectious Diseases, 2020, 70, 193-199.	2.9	86

#	Article	IF	Citations
145	Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment. EBioMedicine, 2017, 18, 56-61.	2.7	83
146	Ipilimumab in patients with melanoma and autoimmune disease. , 2014, 2, 35.		82
147	Selective inhibition of low-affinity memory CD8+ T cells by corticosteroids. Journal of Experimental Medicine, 2019, 216, 2701-2713.	4.2	82
148	Neoantigen quality predicts immunoediting in survivors of pancreatic cancer. Nature, 2022, 606, 389-395.	13.7	80
149	TNF in the era of immune checkpoint inhibitors: friend or foe?. Nature Reviews Rheumatology, 2021, 17, 213-223.	3.5	77
150	Health-related quality of life results from the phase III CheckMate 067 study. European Journal of Cancer, 2017, 82, 80-91.	1.3	76
151	Putting the Immunologic Brakes on Cancer. Cell, 2018, 175, 1452-1454.	13.5	75
152	Prognostic value of baseline metabolic tumor volume measured on 18F-fluorodeoxyglucose positron emission tomography/computed tomography in melanoma patients treated with ipilimumab therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 930-939.	3.3	75
153	Morphological characterization of colorectal cancers in The Cancer Genome Atlas reveals distinct morphologyâ€“molecular associations: clinical and biological implications. Modern Pathology, 2017, 30, 599-609.	2.9	74
154	TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma. Cancer Immunology Research, 2021, 9, 1202-1213.	1.6	71
155	Immune Checkpoint Blockade. Hematology/Oncology Clinics of North America, 2014, 28, 585-600.	0.9	70
156	Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials. , 2016, 4, 15.		67
157	Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child. Nature Medicine, 2021, 27, 1646-1654.	15.2	65
158	The importance of animal models in tumor immunity and immunotherapy. Current Opinion in Genetics and Development, 2014, 24, 46-51.	1.5	62
159	Alphavirus Replicon Particles Expressing TRP-2 Provide Potent Therapeutic Effect on Melanoma through Activation of Humoral and Cellular Immunity. PLoS ONE, 2010, 5, e12670.	1.1	57
160	Rapid Eradication of a Bulky Melanoma Mass with One Dose of Immunotherapy. New England Journal of Medicine, 2015, 372, 2073-2074.	13.9	57
161	Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy. Oncolmmunology, 2016, 5, e1151595.	2.1	57
162	Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. European Journal of Cancer, 2021, 144, 182-191.	1.3	57

#	Article	IF	Citations
163	Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab. Journal of the National Cancer Institute, 2017, 109, djw260.	3.0	56
164	Proportions of blood-borne VÎ´1+ and VÎ´2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab. European Journal of Cancer, 2016, 64, 116-126.	1.3	54
165	LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade. Science Translational Medicine, 2021, 13, .	5.8	54
166	Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer. Cell Reports, 2019, 27, 806-819.e5.	2.9	51
167	Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. , 2021, 9, e003277.		49
168	DNA vaccines: an active immunization strategy for prostate cancer. Seminars in Oncology, 2003, 30, 659-666.	0.8	46
169	Shared cancer neoantigens: Making private matters public. Journal of Experimental Medicine, 2018, 215, 5-7.	4.2	46
170	Anatomic position determines oncogenic specificity in melanoma. Nature, 2022, 604, 354-361.	13.7	44
171	The New Era of Cancer Immunotherapy. Advances in Cancer Research, 2015, 128, 1-68.	1.9	41
172	Clonal Abundance of Tumor-Specific CD4 + T Cells Potentiates Efficacy and Alters Susceptibility to Exhaustion. Immunity, 2016, 44, 179-193.	6.6	39
173	Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade. Annals of Surgical Oncology, 2020, 27, 1180-1188.	0.7	39
174	Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma. Melanoma Research, 2003, 13, 189-196.	0.6	38
175	Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review. Oncologist, 2015, 20, 648-652.	1.9	38
176	Combination of Alphavirus Replicon Particleâ€“Based Vaccination with Immunomodulatory Antibodies: Therapeutic Activity in the B16 Melanoma Mouse Model and Immune Correlates. Cancer Immunology Research, 2014, 2, 448-458.	1.6	37
177	Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma. Nature Communications, 2022, 13, 1935.	5.8	37
178	Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer. Molecular Therapy - Oncolytics, 2014, 1, 14004.	2.0	33
179	In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors. Journal of Clinical Investigation, 2019, 129, 3435-3447.	3.9	33
180	Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma. , 2013, 1, 20.		31

#	Article	IF	Citations
181	Genomic profile, smoking, and response to anti-PD-1 therapy in non-small cell lung carcinoma. Molecular and Cellular Oncology, 2016, 3, e1048929.	0.3	31
182	Myocarditis Surveillance in Patients with Advanced Melanoma on Combination Immune Checkpoint Inhibitor Therapy: The Memorial Sloan Kettering Cancer Center Experience. Oncologist, 2019, 24, e196-e197.	1.9	31
183	First-in-human phase 1 single-dose study of TRX-518, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody in adults with advanced solid tumors.. Journal of Clinical Oncology, 2016, 34, 3017-3017.	0.8	30
184	Recruit or Reboot? How Does Anti-PD-1 Therapy Change Tumor-Infiltrating Lymphocytes?. Cancer Cell, 2019, 36, 215-217.	7.7	29
185	Acquired resistance to immunotherapy in MMR-D pancreatic cancer. , 2018, 6, 127.		27
186	Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus. Oncotarget, 2018, 9, 28702-28716.	0.8	27
187	Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study). Journal of Clinical Oncology, 2022, 40, 1059-1067.	0.8	26
188	Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas. Clinical Cancer Research, 2021, 27, 2226-2235.	3.2	25
189	Safety of Infusing Ipilimumab Over 30 Minutes. Journal of Clinical Oncology, 2015, 33, 3454-3458.	0.8	24
190	Strategies for Predicting Response to Checkpoint Inhibitors. Current Hematologic Malignancy Reports, 2018, 13, 383-395.	1.2	23
191	Fundamental immuneâ€“oncogenicity trade-offs define driver mutationÂfitness. Nature, 2022, 606, 172-179.	13.7	23
192	The delicate balance of melanoma immunotherapy. Clinical and Translational Immunology, 2013, 2, e5.	1.7	22
193	Intravitreous Cutaneous Metastatic Melanoma in the Era of Checkpoint Inhibition. Ophthalmology, 2020, 127, 240-248.	2.5	22
194	Clinical Activity, Toxicity, Biomarkers, and Future Development of CTLA-4 Checkpoint Antagonists. Seminars in Oncology, 2015, 42, 573-586.	0.8	21
195	Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma. Cell Reports, 2021, 34, 108620.	2.9	21
196	Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab. Melanoma Research, 2020, 30, 71-75.	0.6	20
197	Adverse events 2.0â€”Let us get SERIOs. European Journal of Cancer, 2019, 112, 29-31.	1.3	19
198	Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment. Experimental Dermatology, 2016, 25, 553-554.	1.4	17

#	Article	IF	Citations
199	Abstract CT037: Genomic analyses and immunotherapy in advanced melanoma. Cancer Research, 2019, 79, CT037-CT037.	0.4	16
200	Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses. , 2022, 10, e003853.		16
201	Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2022, 28, 3990-4002.	3.2	15
202	Successful Treatment of a Patient with Glioblastoma and a Germline POLE Mutation: Where Next?. Cancer Discovery, 2016, 6, 1210-1211.	7.7	14
203	Patient perspectives on ipilimumab across the melanoma treatment trajectory. Supportive Care in Cancer, 2017, 25, 2155-2167.	1.0	14
204	Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067. , 2021, 9, e003743.		14
205	Evidence generation and reproducibility in cell and gene therapy research: A call to action. Molecular Therapy - Methods and Clinical Development, 2021, 22, 11-14.	1.8	13
206	Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. European Journal of Cancer, 2021, 157, 391-402.	1.3	13
207	Detection of Intra-Tumor Self Antigen Recognition during Melanoma Tumor Progression in Mice Using Advanced Multimode Confocal/Two Photon Microscope. PLoS ONE, 2011, 6, e21214.	1.1	12
208	Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma. Cancers, 2022, 14, 2638.	1.7	12
209	A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma. OncoImmunology, 2021, 10, 1898105.	2.1	11
210	Enhanced Responses to Tumor Immunization Following Total Body Irradiation Are Time-Dependent. PLoS ONE, 2013, 8, e82496.	1.1	11
211	Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine. Science Translational Medicine, 2022, 14, .	5.8	10
212	PD-L1 Blockade Therapy: Location, Location, Location. Cancer Cell, 2020, 38, 615-617.	7.7	9
213	Progressive choroidal thinning (leptochoroid) and fundus depigmentation associated with checkpoint inhibitors. American Journal of Ophthalmology Case Reports, 2020, 19, 100799.	0.4	9
214	Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia. , 2021, 9, e002569.		9
215	Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions. Journal of Experimental Medicine, 2022, 219, .	4.2	8
216	Genetics and immunology: reinvigorated. OncoImmunology, 2015, 4, e1029705.	2.1	7

#	Article	IF	Citations
217	Checkpoint blockade: the end of the beginning. Nature Reviews Immunology, 2021, 21, 621-621.	10.6	7
218	Markers for Anti-cytotoxic T-lymphocyte Antigen 4 (CTLA-4) Therapy in Melanoma. Methods in Molecular Biology, 2014, 1102, 83-95.	0.4	7
219	Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab. , 2021, 9, e003395.		7
220	Abstract CT018: Intratumor and peripheral Treg modulation as a pharmacodynamic biomarker of the GITR agonist antibody TRX-518 in the first in-human trial. Cancer Research, 2017, 77, CT018-CT018.	0.4	6
221	Isoform specific anti-TGFÎ² therapy enhances antitumor efficacy in mouse models of cancer. Communications Biology, 2021, 4, 1296.	2.0	6
222	Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma. Cancers, 2022, 14, 2300.	1.7	6
223	Therapeutic antibody activation of the glucocorticoid-induced TNF receptor by a clustering mechanism. Science Advances, 2022, 8, eabm4552.	4.7	5
224	Curbing Tregsâ€™ (Lack of) Enthusiasm. Cell, 2017, 169, 981-982.	13.5	4
225	Characteristics and probability of survival for patients with advanced melanoma who live five or more years after initial treatment with immune checkpoint blockade (ICB).. Journal of Clinical Oncology, 2021, 39, 9534-9534.	0.8	4
226	Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness. JCI Insight, 2021, 6, .	2.3	2
227	Immigration in science. Journal of Experimental Medicine, 2020, 217, .	4.2	2
228	Patient-Physician Communication in the 21st Century. Trends in Immunology, 2016, 37, 347-349.	2.9	1
229	Refusing to TAP out: 16 new human TEIPPs identified. Journal of Experimental Medicine, 2018, 215, 2233-2234.	4.2	1
230	DNA Immunization Against Melanoma Antigens Enhances Tumor Immunity in Mouse Models of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).. Blood, 2004, 104, 304-304.	0.6	0
231	Alan Houghton. Pigment Cell and Melanoma Research, 2012, 25, 401-401.	1.5	0
232	Reply to A. Indini et al. Journal of Clinical Oncology, 2016, 34, 1018-1019.	0.8	0
233	Reply to: Combining TNF blockade with immune checkpoint inhibitors in patients with cancer. Nature Reviews Rheumatology, 2021, 17, 577-578.	3.5	0
234	DNA Immunization Against Melanoma Antigens Enhances Tumor Immunity in Mice Following Sub-Lethal Irradiation and Immune Reconstitution.. Blood, 2004, 104, 3057-3057.	0.6	0

#	Article	IF	Citations
235	Chromatin State Dynamics Underlying CD8 T Cell Differentiation and Dysfunction in Cancer. Blood, 2016, 128, 861-861.	0.6	0
236	Reply to T. Olivier et al. Journal of Clinical Oncology, 2022, , JCO2200209.	0.8	0